An Adverse Prognostic Effect of Homozygous TET2 Mutational Status on the Relapse Risk of Acute Myeloid Leukemia Patients of Normal Karyotype

• Published in: Blood 2014-12, Vol.124 (21), p.1052-1052
• Main Authors: Ahn, Jae-Sook, Kim, Hyeoung-Joon, Kim, Yeo-Kyeoung, Lee, Il-Kwon, Kim, Nan Young, Minden, Mark D, Jung, Chul Won, Jang, Jun-Ho, Kim, Hee-Je, Moon, Joon Ho, Sohn, Sang Kyun, Won, Jong-Ho, Kim, Sung-Hyun, Kim, Namshin, Yoshida, Kenichi, Ogawa, Seishi, Kim, Dennis Dong Hwan
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V124.21.1052.1052

Purpose Ten-eleven-translocation oncogene family member 2 (TET2) mutations play leukemogenic roles in patients with acute myeloid leukemia (AML). However, the prognostic significance of such mutations in normal-karyotype (NK) AML patients remains controversial, especially that of homozygous TET2 mutations. n the present study, we attempted 1) to evaluate the prevalence of TET2 mutations in NK-AML patients; 2) to clarify the prognostic role played by TET2 mutation, especially homozygous mutation, in NK-AML patients; and, 3) to analyze associations among TET2 mutations and other mutations frequently observed in NK-AML patients, including those in FLT3-ITD, NPM1, and CEBPA. Patients and Methods We included 407 patients with NK-AML in the present study. NK-AML patients were diagnosed from October 1998 to September 2012 in seven participating institutes, and the median patient age was 52 years (range, 15–84 years). Sixty-five different TET2 mutations were detected in 54 patients (13.3%), of which 13 nonsense, 30 frameshift, and 22 missense and, homozygous mutations in 14 patients (25.9%) among TET2 mutated patients. Results A TET2 mutation was associated with poor prognostic features such as older age (p